Alexander Strom

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2344797/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	BOND study: a randomised double-blind, placebo-controlled trial over 12 months to assess the effects of benfotiamine on morphometric, neurophysiological and clinical measures in patients with type 2 diabetes with symptomatic polyneuropathy. BMJ Open, 2022, 12, e057142.	1.9	9
2	High-intensity interval training for 12Âweeks improves cardiovascular autonomic function but not somatosensory nerve function and structure in overweight men with type 2 diabetes. Diabetologia, 2022, 65, 1048-1057.	6.3	8
3	Association of cardiac autonomic dysfunction with higher levels of plasma lipid metabolites in recent-onset type 2 diabetes. Diabetologia, 2021, 64, 458-468.	6.3	20
4	Interaction between magnesium and methylglyoxal in diabetic polyneuropathy and neuronal models. Molecular Metabolism, 2021, 43, 101114.	6.5	7
5	Progression and regression of nerve fibre pathology and dysfunction early in diabetes over 5 years. Brain, 2021, 144, 3251-3263.	7.6	14
6	Neuron-specific biomarkers predict hypo- and hyperalgesia in individuals with diabetic peripheral neuropathy. Diabetologia, 2021, 64, 2843-2855.	6.3	25
7	Impairment in Baroreflex Sensitivity in Recent-Onset Type 2 Diabetes Without Progression Over 5 Years. Diabetes, 2020, 69, 1011-1019.	0.6	16
8	Polyneuropathy is inadequately treated despite increasing symptom intensity in individuals with and without diabetes (PROTECT followâ€up study). Journal of Diabetes Investigation, 2020, 11, 1272-1277.	2.4	12
9	Risk of diabetes-associated diseases in subgroups of patients with recent-onset diabetes: a 5-year follow-up study. Lancet Diabetes and Endocrinology,the, 2019, 7, 684-694.	11.4	364
10	Augmented Corneal Nerve Fiber Branching in Painful Compared With Painless Diabetic Neuropathy. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 6220-6228.	3.6	12
11	Emerging Biomarkers, Tools, and Treatments for Diabetic Polyneuropathy. Endocrine Reviews, 2019, 40, 153-192.	20.1	140
12	Deficits in systemic biomarkers of neuroinflammation and growth factors promoting nerve regeneration in patients with type 2 diabetes and polyneuropathy. BMJ Open Diabetes Research and Care, 2019, 7, e000752.	2.8	12
13	Painful and painless neuropathies are distinct and largely undiagnosed entities in subjects participating in an educational initiative (PROTECT study). Diabetes Research and Clinical Practice, 2018, 139, 147-154.	2.8	45
14	Myeloperoxidase, superoxide dismutaseâ€3, cardiometabolic risk factors, and distal sensorimotor polyneuropathy: The KORA F4/FF4 study. Diabetes/Metabolism Research and Reviews, 2018, 34, e3000.	4.0	18
15	Differential associations of lower cardiac vagal tone with insulin resistance and insulin secretion in recently diagnosed type 1 and type 2 diabetes. Metabolism: Clinical and Experimental, 2018, 79, 1-9.	3.4	25
16	A Systemic Inflammatory Signature Reflecting Cross Talk Between Innate and Adaptive Immunity Is Associated With Incident Polyneuropathy: KORA F4/FF4 Study. Diabetes, 2018, 67, 2434-2442.	0.6	36
17	Differential Patterns of Impaired Cardiorespiratory Fitness and Cardiac Autonomic Dysfunction in Recently Diagnosed Type 1 and Type 2 Diabetes. Diabetes Care, 2017, 40, 246-252.	8.6	26
18	Cardiorespiratory Fitness and Cardiac Autonomic Function in Diabetes. Current Diabetes Reports, 2017, 17, 125.	4.2	21

ALEXANDER STROM

#	Article	IF	CITATIONS
19	Patterns of cutaneous nerve fibre loss and regeneration in type 2 diabetes with painful and painless polyneuropathy. Diabetologia, 2017, 60, 2495-2503.	6.3	54
20	Lower serum extracellular superoxide dismutase levels are associated with polyneuropathy in recent-onset diabetes. Experimental and Molecular Medicine, 2017, 49, e394-e394.	7.7	29
21	Association of transketolase polymorphisms with measures of polyneuropathy in patients with recently diagnosed diabetes. Diabetes/Metabolism Research and Reviews, 2017, 33, e2811.	4.0	22
22	Spatial analysis improves the detection of early corneal nerve fiber loss in patients with recently diagnosed type 2 diabetes. PLoS ONE, 2017, 12, e0173832.	2.5	12
23	Adiponectin, markers of subclinical inflammation and nerve conduction in individuals with recently diagnosed type 1 and type 2 diabetes. European Journal of Endocrinology, 2016, 174, 433-443.	3.7	38
24	Overexpression of cutaneous mitochondrial superoxide dismutase in recent-onset type 2 diabetes. Diabetologia, 2015, 58, 1621-1625.	6.3	9
25	Increased prevalence of cardiac autonomic dysfunction at different degrees of glucose intolerance in the KORA S4 survey. Diabetologia, 2015, 58, 1118-1128.	6.3	85
26	Early Detection of Nerve Fiber Loss by Corneal Confocal Microscopy and Skin Biopsy in Recently Diagnosed Type 2 Diabetes. Diabetes, 2014, 63, 2454-2463.	0.6	270
27	Pronounced Reduction of Cutaneous Langerhans Cell Density in Recently Diagnosed Type 2 Diabetes. Diabetes, 2014, 63, 1148-1153.	0.6	17